Anti-CLEC12A antibody therapy for multiple sclerosis and neuroinflammatory diseases

Overview

This research presents a novel therapeutic approach for multiple sclerosis (MS) and other neuroinflammatory diseases by targeting CLEC12A, a specific C-type lectin receptor that mediates myeloid cell adhesion and transmigration across the inflamed blood-brain barrier (BBB). The approach uses blocking antibodies to inhibit the trafficking of dendritic cells and other myeloid cells into the central nervous system, thereby reducing neuroinflammation and demyelination.

Preclinical validation in both chronic progressive and relapsing-remitting experimental autoimmune encephalomyelitis (EAE) mouse models demonstrated that a single dose of anti-CLEC12A blocking antibody delayed disease onset, attenuated clinical symptoms, restored body weight, and reduced demyelination. This mechanism-based strategy represents a potentially safer alternative to existing MS therapies by specifically blocking immune cell invasion rather than broadly suppressing the immune system.

Technical specifications

Key features:

• Target identification: CLEC12A (also known as MICL) identified as a critical C-type lectin receptor on dendritic cells mediating adhesion and transmigration across the inflamed BBB
• Blocking antibody approach: Anti-CLEC12A monoclonal antibody blocks myeloid cell trafficking into the CNS
• Validated efficacy in progressive EAE model: BL/6 inducible EAE mice showed delayed disease onset, attenuated disease scores, and 50% body weight regain after antibody administration on Day 7
• Validated efficacy in relapsing-remitting EAE model: PLP-immunized SJL/J mice demonstrated similar therapeutic benefits
• Reduced CNS infiltration: Treatment decreased myeloid cell infiltration and demyelination within the central nervous system
• In vivo imaging capability: Near-infrared imaging of EAE mice established correlation between dendritic cell accumulation in CNS and inflammation severity

Future validation plans:

• Identification of the CLEC12A ligand on brain endothelium using glycan array technology
• Mechanistic studies on receptor triggering and internalization via flow cytometry and confocal imaging
• Phosphoproteomics analysis of downstream signaling molecules
• Comparative efficacy and safety evaluation against current FDA-approved MS therapies
• Cytokine profiling and immune balance assessment in progressive and relapsing-remitting EAE models

Technology readiness level

This therapeutic approach is currently at an early preclinical stage of development. The technology has demonstrated proof-of-concept efficacy in two well-established mouse models of multiple sclerosis (chronic progressive and relapsing-remitting EAE), with statistically significant results (P<0.05). Key mechanistic questions regarding the CLEC12A ligand on brain endothelium and downstream signaling pathways remain to be elucidated. Additional preclinical studies are planned to evaluate comparative efficacy, safety, and immune balance before potential advancement toward IND-enabling studies and clinical development.